• Featured Story

    top stock picks

    The Money Morning 2015 top stock picks show that biotech is still red-hot. But elsewhere in tech, particularly in semiconductors, we see another exciting market development for 2015.

    Our 2015 top stock picks list still has the same two biotech names, Prothena Corp. Plc (Nasdaq: PRTA) and Lannett Company Inc. (NYSE: LCI), leading the pack. But Novavax Inc. (Nasdaq: NVAX), a biotech that corrected late March, is back in the No. 3 spot. Then there are semiconductors, which are also seeing a good year.

    Here's our full list of our top performing stock picks so far in 2015...

biotech stocks

2015 Top Stock Picks: SLCA, PRTA, LCI

tech stocks in 2015

Our 2015 top stock picks include a number of biotech stocks, a "frac sand" company, and one company that may be overheating.

Topping the list of our 2015 top stock picks include red-hot biotech names. Crude oil prices are still weak - a function of increased U.S. domestic energy production - but that hasn't soured gains for this frac sand company.

But be warned, not all of these top stocks are a buy...

Why Gilead (Nasdaq: GILD) Is Still A Biotech Stock to Buy

Nasdaq: GILD

Gilead Sciences Inc. (Nasdaq: GILD) is facing criticism again this week for its highly priced Hepatitis C drug Sovaldi. The drug costs $1,000 per pill.

According to The Wall Street Journal, many states have restricted access to the drug, leaving some patients unable to afford the treatment.

But despite the criticism, Gilead (Nasdaq: GILD) stock remains one of the best biotech stocks to buy today. Here's why...

The Best Cheap Stocks to Invest in Now with Breakout Potential

cheap stocks to invest in

The biotech industry is offering some of the best cheap stocks to invest in now.

You see, biotech stocks have faltered in the last two weeks. Since March 20, the Nasdaq Biotechnology Index has dipped nearly 7%.

But this isn't a time to sell. We're adding to our biotech stock positions now. Here are the best cheap stocks to invest in today...

How to Profit from America's $20 Billion Waistline War

Top pharmaceutical companies

Weight loss is a $20 billion per year industry. Yet, it seems the more we spend on shedding pounds, the more pounds we have to shed. Today, two-thirds of adults and one-third of children in the U.S. are overweight or obese, and the numbers are climbing.

With a growing market of that magnitude and so much money changing hands, it's no wonder investors' eyes light up when they hear the words "new obesity drug."

But if you want to find the "gold in those hills," that is, to invest in a stock that will really pay off, you have to know where to look.

Because if you stake a claim in the wrong place, you may lose more weight from your wallet than your waistline...

Sell-Off in Biotech Stocks Making for Attractive Entry Points

U.S. stock futures

Last week on our roundup of the 2015 top stocks to invest in, we highlighted biotech stocks for their explosive growth in 2015 and their continued potential.

And while biotech stocks got creamed this past week. They're still among the best investments for 2015.

Just look at our top stocks to invest in for 2015, which still features a few biotech stocks as our best performers...

Is This a Biotech Bubble?

biotech bubble

Wall Street pundits are claiming we are on the precipice of a biotech bubble because biotechnology stocks have been soaring. The Nasdaq Biotechnology Index has climbed 44% in the last year. The Nasdaq Composite and S&P 500 have climbed just 9% and 11% in the same time.

But it's the last week that has traders panicked about "bubble" territory.

From March 20 through March 26, the Nasdaq biotech index dipped 7%. The S&P biotech index dropped almost 11%.

These tremors could signify a correction in the coming months - but make no mistake - the "bubble" is not about to burst on biotech stocks...

This $6 Biotech Stock Is Opening the Door to True "Personalized Medicine"

Stealth Profits Trader – update from D.R. Check your email or moneymappress.com. Reply STOP to opt out of texts

We've found a great biotech stock that's riding a super powerful trend. The company develops and markets diagnostic technologies.

And its technology is likely to stir the $50 billion in vitro diagnostics (IVD) industry. Plus, an "outsider" investor just recently bought up 15% of the company's shares.

Here's why we're loving this biotech stock...

Top Pharmaceutical Companies Continue Massive M&A – Here's Your Profit Play

Top pharmaceutical companies

Two of the world's top pharmaceutical companies have announced a merger today (Thursday), and that's another major buy signal for one of our favorite profit opportunities.

AbbVie Inc. (NYSE: ABBV) officials announced they will purchase Pharmacyclics Inc. (Nasdaq: PCYC) for roughly $21 billion.

 

The deal gives Abbvie access to one of the world's top-selling cancer drugs, Imbruvica. Revenue from Imbruvica alone is expected to hit $1 billion in 2015 and $5.8 billion by 2020.

Another of Our Top Stocks to Invest in Is Up 50% in 2015

Biotech stocks have been hot this year. Two of our top stocks to invest in are up more than 50% on the year.

Last week we talked about Novavax Inc. (Nasdaq: NVAX). While still on a roll this year, we cautioned investors. It's a biotech company still in its clinical-stage and could be overheating.

Here's another biotech that's hot, but still has room to keep going...

60 Biotech Companies to Go Public Before April 1

biotech companies

Biotechnology is tech's fastest-growing sector. In fact, there are more than 100 biotech companies set to go public in 2015.

Of those 100 IPOs, 60 are expected to launch before April 1. So you have to move fast to ride this $320 billion biotech wave.

Those IPOs are all but certain to keep the biotech bull market going through the year. Biotech stocks have soared 290% in the past five years. That's more than triple the S&P's 88%.

And biotech IPOs are not the only catalysts that will lift biotech shares across the board in 2015.

© 2015 Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201, Email: customerservice@MoneyMorning.com